Botanix will be presenting at the 27th EADV Congress in Paris, France
Key highlights
· Botanix will be presenting at the 27th EADV Congress in Paris, France
· Botanix will provide an update on its Phase 2 products and other pipeline products
· Botanix will have the opportunity to engage with market leading global pharmaceuticals organisations and researchers
Philadelphia PA and Sydney Australia, 13th September 2018 -- Medical dermatology company Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or the “Company”) is pleased to release an updated company presentation for the 27th Congress of the European Academy of Dermatology and Venerology (EADV Congress), held in Paris, France.
To read the ASX announcement, please click here
Have you seen our earlier videos?
Click here to visit our new YouTube page
Click here to watch an introduction to Botanix Pharmaceuticals
Click here to watch the BTX 1204 Presentation
Click here to watch an interview with CMO, Dr Stephane Levy
For more information, please visit www.botanixpharma.com or follow us on Twitter @BotanixPharma
General Enquiries
Matt Callahan
Botanix Pharmaceuticals
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com
Investor Enquiries
Joel Seah
Vesparum Capital
P: +61 3 8582 4800
E: botanixpharma@vesparum.com
Media Enquiries
Julia Maguire
The Capital Network
P: +61 419 815 386
E: julia@thecapitalnetwork.com.au
